Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Besremi in maintaining deep molecular remission in CML
NCT03117816Phase 3Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- May 2017
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ropeginterferon alfa-2b in Chronic Myeloid Leukemia (CML), sponsored by Philipps-Universität Marburg. Started May 2017; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT03117816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117816.